Angiotensin converting enzyme 2 and diminazene
Authors:
- Sheila K. PatelSPSheila K. Patel
- Louise M. BurrellLBLouise M. Burrell
- 1 September 2016
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 25 (5) , 384-395
Abstract
Angiotensin converting enzyme 2 (ACE2) is an important regulator of the renin-angiotensin system through actions to degrade angiotensin II. Loss of ACE2 can contribute to the development and progression of cardiovascular disease, and experimental studies have highlighted a beneficial role for novel therapeutic approaches that activate or replenish tissue ACE2. This review focuses on experimental studies that have used the off-target effects of the antitrypanosomal agent, diminazene aceturate (DIZE) to activate ACE2. In cardiovascular disease, activation of the classical renin-angiotensin system and depletion of ACE2 leads to pathophysiological changes. One approach to activate ACE2 involves the drug DIZE, which has been shown to have beneficial effects in experimental models of hypertension, pulmonary hypertension, myocardial infarction, stroke, atherosclerosis, type 1 diabetes, and eye disease. The precise mechanism of action of DIZE to activate ACE2 remains under scrutiny. Activation of ACE2 may represent an important therapeutic approach in cardiovascular disease. To date, most studies have focused on the off-target actions of DIZE, in experimental models of disease. More research is required to determine the exact mechanism of action of DIZE and evaluate its therapeutic potential in comparison with currently available clinical interventions. There are no clinical studies of DIZE, and its side-effects, and toxicity make such studies unlikely. Hence, new methods of selectively activating or replenishing ACE2 will be needed in the future if this approach is to be used in a clinical context.Keywords
This publication has 51 references indexed in Scilit:
- Angiotensin‐converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitorExperimental Physiology, 2008
- ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHRPhysiological Genomics, 2006
- Characterization of Angiotensin Converting Enzyme-2 (ACE2) in Human UrineInternational Journal of Peptide Research and Therapeutics, 2006
- The cardiovascular continuum and renin–angiotensin–aldosterone system blockadeJournal Of Hypertension, 2005
- Myocardial infarction increases ACE2 expression in rat and humansEuropean Heart Journal, 2005
- ACE2, a new regulator of the renin–angiotensin systemTrends in Endocrinology & Metabolism, 2004
- Molecular Mechanisms of Inhibition of Vascular Growth by Angiotensin-(1-7)Hypertension, 2003
- Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor MasProceedings of the National Academy of Sciences, 2003
- Angiotensin-converting enzyme 2 is an essential regulator of heart functionNature, 2002
- A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9Circulation Research, 2000